Shikiar Asset Management’s Fortress Biotech 9.375% Series A Preferred Stock FBIOP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-15,000
| Closed | -$262K | – | 78 |
|
|
2023
Q2 | $262K | Sell |
15,000
-37,500
| -71% | -$667K | 0.08% | 65 |
|
|
2023
Q1 | $966K | Buy |
+52,500
| New | +$1.02M | 0.34% | 42 |
|
|
2022
Q3 | $1.16M | Sell |
62,000
-13,000
| -17% | -$251K | 0.47% | 40 |
|
|
2022
Q2 | $1.37M | Sell |
75,000
-20,460
| -21% | -$424K | 0.53% | 36 |
|
|
2022
Q1 | $2.29M | Sell |
95,460
-23,800
| -20% | -$581K | 0.65% | 33 |
|
|
2021
Q4 | $3.09M | Sell |
119,260
-1,550
| -1% | -$40.2K | 0.79% | 30 |
|
|
2021
Q3 | $3.13M | Sell |
120,810
-3,500
| -3% | -$90.4K | 0.88% | 31 |
|
|
2021
Q2 | $3.23M | Buy |
124,310
+3,100
| +3% | +$79.1K | 0.91% | 32 |
|
|
2021
Q1 | $2.88M | Buy |
121,210
+12,350
| +11% | +$271K | 0.97% | 33 |
|
|
2020
Q4 | $2.11M | Buy |
108,860
+4,350
| +4% | +$81.7K | 0.76% | 32 |
|
|
2020
Q3 | $1.97M | Buy |
104,510
+22,200
| +27% | +$408K | 0.76% | 30 |
|
|
2020
Q2 | $1.47M | Sell |
82,310
-1,000
| -1% | -$18.1K | 0.67% | 32 |
|
|
2020
Q1 | $1.26M | Buy |
83,310
+53,500
| +179% | +$1.04M | 0.85% | 28 |
|
|
2019
Q4 | $611K | Buy |
+29,810
| New | +$614K | 0.2% | 62 |
|
Shikiar Asset Management's FBIOP Position: Q3 2023 in Review
Shikiar Asset Management sold out of Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) in Q3 2023, closing a stake of 15,000 shares — an estimated $262K sold.
Shikiar Asset Management first reported a position in FBIOP in Q4 2019 and held it in 14 quarters. The position peaked at $3.23M in Q2 2021. 0 funds tracked by Wall St. Rank hold FBIOP as of Q3 2023.
- Shikiar Asset Management reported no remaining Fortress Biotech 9.375% Series A Preferred Stock position as of Q3 2023 after selling out during the quarter.
- Shikiar Asset Management sold 15,000 Fortress Biotech 9.375% Series A Preferred Stock shares in Q3 2023, an estimated $262K.
- Shikiar Asset Management first reported a position in Fortress Biotech 9.375% Series A Preferred Stock in Q4 2019 and held it in 14 quarters.
- Shikiar Asset Management's Fortress Biotech 9.375% Series A Preferred Stock position peaked at $3.23M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Fortress Biotech 9.375% Series A Preferred Stock as of Q3 2023.
Based on Shikiar Asset Management's 13F filing for Q3 2023, filed 31 Oct 2023.